Zymeworks Added to Nasdaq Biotechnology Index

VANCOUVER, British Columbia, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced it is expected to be added to the Nasdaq Biotechnology Index (Nasdaq: NBI) (the “NBI”). Zymeworks’ addition to the NBI will become effective prior to the market open on Monday, December 18, 2023.

The NBI is designed to track the performance of a set of securities listed on The Nasdaq Stock Market that are issued by companies classified as either biotechnology or pharmaceutical companies according to the Industry Classification Benchmark. Companies in the NBI must meet certain eligibility requirements, including, but not limited to, minimum market capitalization, average daily trading volume, and seasoning as a public company. The NBI is evaluated annually in December and is calculated under a modified capitalization-weighted methodology. The NBI is currently comprised of approximately 250 companies. For more information about the NBI, visit: https://indexes.nasdaqomx.com/Index/Overview/NBI

About Zymeworks Inc.

Zymeworks Inc. (Nasdaq: ZYME) is a global biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks' mission is to make a meaningful difference for people impacted by difficult-to-treat cancers and other serious diseases. Zymeworks' complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using Zymeworks' proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz), granting each of BeiGene and Jazz with exclusive rights to develop and commercialize zanidatamab in different territories. Zanidatamab is currently being evaluated in global Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials as a treatment for patients with HER2-expressing cancers. Zymeworks' next clinical candidate, zanidatamab zovodotin (ZW49), is a HER2-targeted bispecific antibody-drug conjugate (ADC) developed using Zymeworks' proprietary Azymetric™ and ZymeLink™ Auristatin technologies. Zanidatamab zovodotin is currently being evaluated in a Phase 1 clinical trial for patients with a variety of HER2-expressing, HER2-amplified or HER2-mutant cancers. Zymeworks is also advancing a deep pipeline of product candidates based on its experience and capabilities in both ADC and multispecific antibodies (MSAT). In addition to Zymeworks' wholly owned pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on X.

Cautionary Note Regarding Forward-Looking Statements

This press release includes “forward-looking statements” or information within the meaning of the applicable securities legislation, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include, but are not limited to, statements that relate to the anticipated inclusion in the Nasdaq Biotechnology Index following the annual reconstitution, risks and uncertainties relating to the anticipated trading of Zymeworks securities, and other information that is not historical information. When used herein, words such as “plan”, “believe”, “expect”, “may”, “continue”, “anticipate”, “potential”, “will”, “progress”, and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Zymeworks’ current expectations and various assumptions. Zymeworks believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Zymeworks may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various factors, including, without limitation: risks relating to becoming included and remaining included in the Nasdaq Biotechnology Index; risks and uncertainties relating to the trading of our securities as it relates to the Nasdaq Biotechnology Index annual reconstitution and the inclusion of Zymeworks on the Nasdaq Biotechnology Index following such reconstitution; clinical trials may not demonstrate safety and efficacy of any of Zymeworks’ or its collaborators’ product candidates; any of Zymeworks’ or its partners’ product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; Zymeworks may not achieve milestones or receive additional payments under its collaborations; the impact of pandemics and other health crises on Zymeworks’ business, research and clinical development plans and timelines and results of operations, including impact on its clinical trial sites, collaborators, and contractors who act for or on Zymeworks’ behalf; inability to maintain or enter into new partnerships or strategic collaborations; regulatory agencies may impose additional requirements or delay the initiation of clinical trials; the impact of new or changing laws and regulations; market conditions; and the other risks described under “Risk Factors” in Zymeworks’ Quarterly Report on Form 10-Q for its quarter ended September 30, 2023 (a copy of which may be obtained at www.sec.gov and www.sedar.com). Although Zymeworks believes that such forward-looking statements are reasonable, there can be no assurance they will prove to be correct. Investors should not place undue reliance on forward-looking statements. The above assumptions, risks and uncertainties are not exhaustive. Forward-looking statements are made as of the date hereof and, except as may be required by law, Zymeworks undertakes no obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances, or to reflect the occurrences of unanticipated events.

Contacts:

Investor Inquiries:

Shrinal Inamdar
Director, Investor Relations
(604) 678-1388
ir@zymeworks.com   

Media Inquiries:

Diana Papove
Director, Corporate Communications
(604) 678-1388
media@zymeworks.com



Zymeworks Added to Nasdaq Biotechnology Index

THỦ THUẬT HAY

Top Trình Giả Lập iOS Trên Window Năm 2023 Và Link Tải

iOS của Apple là một trong những hệ điều hành phổ biến và an toàn nhất. Đó là lý do tại sao thật khó để chạy và thử nghiệm các ứng dụng gốc iOS trong một môi trường khác và chỉ các thiết bị của Apple mới có thể hỗ trợ

Những phím tắt Kodi hữu ích mà bạn nên biết

Cũng tương tự như những phần mềm nghe nhạc khác như KMPlayer, VLC Media Player thì Kodi cũng có hệ thống phím tắt riêng. Vậy mời các bạn cùng theo dõi bài viết dưới đây để nắm rõ những phím tắt Kodi thông dụng, giúp quá

Cách hóa thân vào trò chơi Squid Game trên Roblox bằng điện thoại

Bộ phim Hàn Quốc Squid Game nổi đình nổi đám đang phủ sóng trên khắp các trang mạng xã hội, hóa thân thành người chơi để chinh phục trò chơi con mực (Squid Game) không còn là vấn đề khó khăn.

Công cụ "dẫn đường online" buộc phải có trên smartphone

Gửi kết quả từ Google Maps sang điện thoại là việc chúng ta tìm kiếm đường đi qua Google Maps trên máy tính, rồi gửi kết quả này sang một điện thoại bất kỳ dưới dạng tin nhắn.

Cách lấy giáp trong game Megaman X8

Trong Megaman X8 sở hữu rất nhiều các món đồ bí mật và Icarus và Hermes là 2 trong số những bộ giáp mạnh nhất mà bạn cần phải có trong game. Với lấy giáp trong Megaman X8 qua bài viết dưới đây sẽ là tài liệu tham khảo

ĐÁNH GIÁ NHANH

Đánh giá Nvidia GeForce RTX 2080: Hiệu năng tuyệt vời nhưng giá thành đắt đỏ

Giá của RTX 2080 được Nvidia đưa ra là $799 cao hơn khá nhiều so với GTX 1080 khi ra mắt là $549. Tuy nhiên đây là giá của phiên bản Founders (phiên bản cao cấp của GPU của Nvidia). Bạn sẽ tìm thấy các phiên bản khác

So sánh iPhone 13 Pro Max và iPhone 11 Pro Max: Có nên nâng cấp không?

Bạn đang băn khoăn không biết có nên nâng cấp iPhone 11 Pro Max lên iPhone 13 Pro Max hay không? Vậy thì hãy cùng chúng tôi đem chúng đặt lên bàn cân và so sánh iPhone 13 Pro Max và iPhone 11 Pro Max để tìm câu trả lời

Đánh giá chi tiết Xiaomi Mi 5s Plus

Xiaomi Mi 5s Plus là một chiếc Phablet có hiệu năng mạnh nhất trên thị trường hiện nay, camera kép và giá tốt. Hôm nay chúng ta sẽ cùng đánh giá chi tiết máy.